213Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells

Nuclear Medicine and Biology

Volumn 41, Issue 1, 2014, Pages 68-76

  Pickhard, Anja ^a   Piontek, Guido ^a   Seidl, Christof ^a   Kopping, Samuel ^a   Blechert, Birgit ^a   Mißlbeck, Martin ^a   Brockhoff, Gero ^b   Bruchertseifer, Frank ^c   Morgenstern, Alfred ^c   Essler, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

emitter 213Bi; Apoptosis; Cell cycle arrest; Cytotoxicity; Head and neck squamous cell carcinoma; Radioimmunotherapy; UD SCC5 cells

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BISMUTH MATUZUMAB BI 213 RADIOIMMUNOCONJUGATE; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PUMA PROTEIN; UNCLASSIFIED DRUG; BISMUTH; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ALPHA RADIATION; APOPTOSIS; ARTICLE; BAX GENE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG BINDING; DRUG CYTOTOXICITY; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GADD45 GENE; GENE ACTIVATION; GENE INDUCTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; LD 50; MOLECULAR DYNAMICS; P21 WAF GENE; PROTEIN EXPRESSION; PUMA GENE; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; S PHASE CELL CYCLE CHECKPOINT; Α-EMITTER (213)BI; ANTIBODY SPECIFICITY; CELL-CYCLE ARREST; CYTOTOXICITY; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; LINEAR ENERGY TRANSFER; PATHOLOGY; RADIATION EXPOSURE; RADIOTHERAPY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR CELL LINE; UD-SCC5 CELLS;

Α-EMITTER (213)BI; APOPTOSIS; CELL-CYCLE ARREST; CYTOTOXICITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; RADIOIMMUNOTHERAPY; UD-SCC5 CELLS;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; APOPTOSIS; BISMUTH; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; G1 PHASE CELL CYCLE CHECKPOINTS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCONJUGATES; LINEAR ENERGY TRANSFER; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; X-RAY THERAPY;

EID: 84888385531     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.09.010     Document Type: Article

References (43)

1. Hunter K.D., Parkinson E.K., Harrison P.R. Profiling early head and neck cancer. Nat Rev Cancer 2005, 5:127-135.
2. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. N Engl J Med 2008, 359:1143-1154.
3. Jang S.J., Chiba I., Hirai A., Hong W.K., Mao L. Multiple oral squamous epithelial lesions: are they genetically related?. Oncogene 2001, 20:2235-2242.
4. Jin C., Jin Y., Wennerberg J., Akervall J., Dictor M., Mertens F. Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet 2002, 132:85-96.
5. Braakhuis B.J., Tabor M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63:1727-1730.
6. Rademakers S.E., Span P.N., Kaanders J.H., Sweep F.C., van der Kogel A.J., Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008, 2:41-53.
7. Bernier J., Bentzen S.M. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003, 39:560-571.
8. Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefèbvre J.L., Greiner R.H., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350:1945-1952.
9. Bernier J., Bentzen S.M., Vermorken J.B. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009, 6:266-277.
10. Cassell A., Grandis J.R. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs 2010, 19:709-722.
11. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
12. Burtness B., Goldwasser M.A., Flood W., Mattar B. Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
13. Specenier P., Vermorken J.B. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011, 11:511-524.
14. Bauman J.E., Michel L.S., Chung C.H. New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 2012, 24:235-242.
15. Specenier P, Vermorken JB. Biologic therapy in head and neck cancer: a road with hurdles. ISRN Oncol 2012:163752.
16. Tinhofer I., Klinghammer K., Weichert W., Knödler M., Stenzinger A., Gauler T., et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011, 17:5197-5204.
17. Galer C.E., Corey C.L., Wang Z., Younes M.N., Gomez-Rivera F., Jasser S.A., et al. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011, 33:189-198.
18. Niu G., Sun X., Cao Q., Courter D., Koong A., Le Q.T., et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010, 16:2095-2105.
19. 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 2010, 9:2297-2308.
20. Kim Y.S., Brechbiel M.W. An overview of targeted alpha therapy. Tumour Biol 2012, 33:573-590.
21. 213Bi. Curr Radiopharm 2011, 4:295-305.
22. 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 2009, 50:1700-1708.
23. 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. Plos One 2013, 8:e64730.
24. Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007, 29:163-188.
25. Apostolidis C., Molinet R., Rasmussen G., Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005, 77:6288-6291.
26. Morgenstern A., Bruchertseifer F., Apostolidis C. Bismuth-213 and actinium-225 - generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr Radiopharm 2012, 5:221-227.
27. Nikula T.K., Curcio M.J., Brechbiel M.W., Gansow O.A., Finn R.D., Scheinberg D.A. A rapid, single vessel method for preparation of clinical grade ligand conjugated antibodies. Nucl Med Biol 1995, 22:387-390.
28. Huber R., Seidl C., Schmid E., Seidenschwang S., Becker K.F., Schuhmacher C., et al. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin Cancer Res 2003, 9(10 Pt 2):3922s-3928s.
29. Noeske K. The binding of crystal violet on deoxyribonucleic acid. Cytophotometric studies on normal and tumor cell nuclei. Histochemie 1996;7:273-87 [German].
30. Hikisz P., Kiliańska Z.M. PUMA, a critical mediator of cell death-one decade on from its discovery. Cell Mol Biol Lett 2012, 17:646-669.
31. Turksma A.W., Braakhuis B.J., Bloemena E., Meijer C.J., Leemans C.R., Hooijberg E. Immunotherapy for head and neck cancer patients: shifting the balance. Immunotherapy 2013, 5:49-61.
32. Harris M., Wang X.G., Jiang Z., Goldberg G.L., Casadevall A., Dadachova E. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol 2011, 3:9.
33. Pickhard A.C., Margraf J., Knopf A., Stark T., Piontek G., Beck C., et al. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer 2011, 11:388.
34. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
35. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
36. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862.
37. Taira N., Yoshida K. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol Histopathol 2012, 27:437-443.
38. Oren M. Decision making by p53. Life, death, and cancer. Cell Death Differ 2003, 10:431-442.
39. Höpker K., Hagmann H., Khurshid S., Chen S., Schermer B., Benzing T., et al. Putting the brakes on p53-driven apoptosis. Cell Cycle 2012, 11:4122-4128.
40. Wu D., Ozaki T., Yoshihara Y., Kubo N., Nakagawara A. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation. J Biol Chem 2013, 288:1353-1364.
41. Gupta K., Thakur V.S., Bhaskaran N., Nawab A., Babcook M.A., Jackson M.W., et al. Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. PLoS One 2012, 7:e52572.
42. Yoshida K., Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 2010, 101:831-835.
43. Friesen C., Glatting G., Koop B., Schwarz K., Morgenstern A., Apostolidis C., et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007, 67:1950-1958.